Addressing Racial Disparities in Clinical Trial Recruitment: Alexis A. Thompson, MD, MPH

One of the issues surrounding hematology care is the underrepresentation of racial and ethnic minorities in clinical trials. At the recent 63rd American Society of Hematology (ASH) Annual Meeting & Exposition in Atlanta, Georgia, Alexis A. Thompson, MD, MPH, past President of ASH and Professor of Pediatrics at Northwestern University's Feinberg School of Medicine, shared her thoughts on strategies for remedying these disparities so that more inclusive care can be provided for patients with h...

Continue reading

Safely Reducing Patient Hospital Stay After CAR T-Cell Therapy: Remote Patient Monitoring With Morie Gertz, MD

While chimeric antigen receptor (CAR) T-cell therapies have revolutionized the treatment landscape for patients with hematologic malignancies, challenges remain in the management of short-term toxicities, most notably cytokine release syndrome and neurologic symptoms. In nearly all cases to date, optimal management has only been achieved through inpatient admission for frequent monitoring; however, an onsite hospital stay can create a significant burden for the patient. As part of a study recent...

Continue reading

i3 Health Publishes T-Cell Lymphoma Education Study in American Society of Hematology Online Program

i3 Health's study focusing on the effectiveness of an online continuing medical education (CME)/nursing continuing professional development (NCPD)–approved activity to improve clinicians' knowledge of therapeutic advances in T-cell lymphoma (TCL) has been published as a 63rd American Society of Hematology (ASH) Annual Meeting & Exposition online abstract

Continue reading

CC-486 Effective for Acute Myeloid Leukemia

The oral hypomethylating agent CC-486, when administered in an escalated dosing schedule (>7 days per 28-day treatment cycle), has been shown to be effective and well tolerated for patients with acute myeloid leukemia (AML) experiencing their first relapse, according to results of a study presented at American Society of Hematology (ASH) Annual Meeting. For the phase 3 international, randomized, double-blind QUAZAR AML-001 trial (NCT01757535), 472 patients with AML were enrolled. To be eligib...

Continue reading

Myeloma: Bortezomib Overcomes Renal Impairment or del17p

​Twelve-year follow-up results of the HOVON-65/GMMG-HD4 study reveal that among transplant-eligible patients with newly diagnosed multiple myeloma, those with renal impairment or chromosome deletion (del) 17p experience the most survival benefit from bortezomib-based induction and maintenance therapy. This prospective, open-label phase 3 trial of the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) and the German Multicenter Myeloma Group (GMMG) enrolled 827 eligible patients aged 18 to 6...

Continue reading


Get the latest updates delivered to your inbox!

Follow Us

Copyright © 2022 Oncology Data Advisor. All rights reserved.